Skip to main
  1. Stocks
  2. Harrow Health Inc
  3. Forecast
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is supported by a strengthened commercial model that is already translating into growth, with 3Q26 revenue of $99.3M up 39% YoY and branded revenue of $83.5M, or about 84% of the total, driven by VEVYE, IHEEZO, and early BYOOVIZ traction. The investment case is reinforced by product-level differentiation and cross-selling leverage: VEVYE posted record quarterly revenue of $39.7M, IHEEZO showed a 58% reduction in discomfort in its randomized study and 65,477 record units in 2Q, and TYRVAYA adds a complementary dry-eye mechanism while expanding prescriber reach in 4Q26. With a broader ophthalmology platform, an 18-product portfolio, and a credible path toward 2026 revenue guidance of $350M-$365M and 2027 quarterly revenue aspirations, the company appears well positioned to compound growth through commercialization and pipeline optionality.

Bears say

Harrow is facing a negative fundamental setup because its reported progress is being masked by heavy execution and reimbursement risk, with 1H’26 revenue of $114.9MM still requiring a very steep 2H’26 ramp to reach management’s $350M–$365M target. The company’s profitability outlook weakened materially when 2026 Adjusted EBITDA guidance was cut to more than $40M from $80M–$100M, even as accounts receivable reached $155.3M versus $75.3M in cash and equivalents as of September 30, 2026. Structural pressures in TRIESENCE, IHEEZO, and VEVYE remain significant, including entrenched cheap generics, payer pushback, and the April 1, 2026 loss of IHEEZO’s ASC pass-through, which could constrain both growth and margins.

HROW has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

HROW Analyst Forecast & Price Prediction

Get the latest HROW stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HROW

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 5 analysts, HROW has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $66.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $66.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


HROW Analyst Forecast & Price Prediction

Get the latest HROW stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HROW

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HROW stock data and trends